
3 Cancer Medicines Maker, Heritage Resorts Owner and Gas Field Operator Stocks With a Strong Future Roadmap: Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation
Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation: ROE of 11.1% to 18.7% and FY22 to FY26 revenue CAGR of 5.6% to 51.8%. Prices as of 18 Nov 2026.
Updated: 19 Nov 2026 • 4:09 pm
Posted by:

Quick Answer
The three oncology generic, resort and gas well stocks to watch are Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation. Their return on equity ranges from 11.1% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.6% to 51.8%. Emcure Pharmaceuticals has the highest return on equity at 18.7%, while Chalet Hotels has the fastest revenue growth at 51.8% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.
Oncology generic, resort and gas well stocks bring together companies with a visible plan for the years ahead. Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation cover a pharmaceuticals company, a premium hotels owner and an oil and gas producer.
This list covers three oncology generic, resort and gas well stocks with complete current figures: Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Oncology Generic, Resort and Gas Well Stocks?
Oncology generic, resort and gas well stocks are listed companies that make branded and generic medicines for India and global markets, own and run premium hotels and resorts in large cities, and explore for and produce crude oil and natural gas. Their earnings depend on medicine demand, hotel occupancy and oil and gas prices.
Oncology Generic, Resort and Gas Well Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 2,334.8 | 33,487 | 32.9 | 36.0 | 18.7 | 0.31 |
| Chalet Hotels | 819.45 | 18,491 | 35.0 | 37.9 | 17.4 | 0.64 |
| Oil and Natural Gas Corporation | 225 | 282,679 | 6.3 | 7.2 | 11.1 | 0.47 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing oncology generic, resort and gas well stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in oncology generic, resort and gas well stocks can use the coming numbers to test whether growth is holding.
Why Do Oncology Generic, Resort and Gas Well Stocks Have a Strong Roadmap in India?
Oncology generic, resort and gas well stocks have a strong roadmap in India because steady demand for medicines, strong luxury travel and steady energy demand keep widening the market for these companies.
- Pharmaceuticals. Patients need affordable medicines.
- Premium hotels. Business and leisure travel fills rooms.
- Oil and gas. Refiners and cities need steady supply.
Why Emcure Pharmaceuticals Features Among These Oncology Generic, Resort and Gas Well Stocks
Among the oncology generic, resort and gas well stocks on this list, Emcure Pharmaceuticals, based in Pune, sells branded generics in India through marketing arms such as Zuventus and Avet, and also serves Europe, Canada and other markets.
Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%.
In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0.
Roadmap: It is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
What to watch: Look at the growth of the India branded business and the pace of new launches abroad.
Why Chalet Hotels Features Among These Oncology Generic, Resort and Gas Well Stocks
Among the cancer medicines, luxury hotels and crude producer shares on this list, Chalet Hotels owns and develops upscale hotels and resorts in key Indian cities such as Mumbai, Bengaluru and Hyderabad, and it also has a growing commercial and retail real estate portfolio. Its hotels operate under leading global brands.
Revenue rose from Rs 530 crore in FY22 to Rs 2,812 crore in FY26, a compound annual growth rate of 51.8%. Net profit grew from Rs 183 crore in FY23 to Rs 645 crore in FY26, which works out to a compound annual growth rate of 52.1%.
The company has a return on equity of 17.4%, a debt to equity ratio of 0.64 and a market capitalisation of Rs 18,491 crore. The stock trades at a P/E of 35.0, below the industry P/E of 37.9.
Roadmap: The company is adding rooms at existing hotels and building new properties in cities where business and leisure travel is growing. Its annuity assets, such as office and retail space, add steady rental income alongside hotel earnings.
What to watch: Track occupancy, average room rates and the progress of new room additions.
Why Oil and Natural Gas Corporation Features Among These Oncology Generic, Resort and Gas Well Stocks
Among the three companies on this list, Oil and Natural Gas Corporation is India's largest producer of crude oil and natural gas, with operations in domestic basins and overseas assets. It also has interests in refining, petrochemicals and gas through group companies.
The company has a return on equity of 11.1%, a debt to equity ratio of 0.47 and a market capitalisation of Rs 282,679 crore. The stock trades at a P/E of 6.3, below the industry P/E of 7.2.
Revenue rose from Rs 498,738 crore in FY22 to Rs 621,019 crore in FY26, a compound annual growth rate of 5.6%. Net profit grew from Rs 32,778 crore in FY23 to Rs 49,793 crore in FY26, which works out to a compound annual growth rate of 15.0%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 207,776 crore.
Roadmap: The company is investing in new wells, deepwater projects and field redevelopment to raise output, and it is entering new energy areas such as gas and renewables. Its large reserve base supports long-term production.
What to watch: Follow production volumes, new field start-ups and realisations.
Emcure Pharmaceuticals vs Chalet Hotels vs Oil and Natural Gas Corporation on Key Financials
The table below sets the three oncology generic, resort and gas well stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Emcure Pharmaceuticals | 5,919 | 9,335 | 12.1% | 941 | 10.1% |
| Chalet Hotels | 530 | 2,812 | 51.8% | 645 | 22.9% |
| Oil and Natural Gas Corporation | 498,738 | 621,019 | 5.6% | 49,793 | 8.0% |
Emcure Pharmaceuticals posts the highest return on equity in this group at 18.7%. Oil and Natural Gas Corporation has the largest FY26 revenue at Rs 621,019 crore, and Chalet Hotels shows the fastest revenue growth with a 51.8% compound annual rate. A useful habit with oncology generic, resort and gas well stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Oncology Generic, Resort and Gas Well Stocks
Every theme carries risks that deserve a check before any decision. For these oncology generic, resort and gas well stocks, the main points are: Long-term cancer medicines, luxury hotels and crude producer shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Travel cycles. Bookings and occupancy follow travel demand.
- Oil and gas prices. Earnings follow crude oil, gas and refining margins.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter oncology generic, resort and gas well stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Oncology Generic, Resort and Gas Well Stocks
Oncology generic, resort and gas well stocks suit investors who prefer to study business strength before price moves. Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation each have a clear plan to grow. Based on the 18 November 2026 close, Emcure Pharmaceuticals trades at Rs 2,334.8, Chalet Hotels at Rs 819.45 and Oil and Natural Gas Corporation at Rs 225. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these oncology generic, resort and gas well stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track oncology generic, resort and gas well stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are oncology generic, resort and gas well stocks?
Ans. Oncology generic, resort and gas well stocks are listed companies that make branded and generic medicines for India and global markets, own and run premium hotels and resorts in large cities, and explore for and produce crude oil and natural gas. Their earnings depend on medicine demand, hotel occupancy and oil and gas prices. This list looks at three of them, Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.
Which oncology generic, resort and gas well stocks are covered in this list?
Ans. This list covers Emcure Pharmaceuticals, Chalet Hotels and Oil and Natural Gas Corporation. Based on the 18 November 2026 close, Emcure Pharmaceuticals traded at Rs 2,334.8, Chalet Hotels at Rs 819.45 and Oil and Natural Gas Corporation at Rs 225. Their return on equity ranges from 11.1% to 18.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.6% to 51.8%.
Why do oncology generic, resort and gas well stocks have a strong future roadmap in India?
Ans. Oncology generic, resort and gas well stocks have a strong roadmap in India because steady demand for medicines, strong luxury travel and steady energy demand keep widening the market for these companies. The main drivers are as follows. Pharmaceuticals. Patients need affordable medicines. Premium hotels. Business and leisure travel fills rooms. Oil and gas. Refiners and cities need steady supply. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Emcure Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 5,919 crore in FY22 to Rs 9,335 crore in FY26, a compound annual growth rate of 12.1%. Net profit grew from Rs 703 crore in FY22 to Rs 941 crore in FY26, which works out to a compound annual growth rate of 7.6%. In the June 2026 quarter, revenue grew 22.7% year on year to Rs 2,583 crore, while net profit rose 36.2% to Rs 292 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.31 and a market capitalisation of Rs 33,487 crore. The stock trades at a P/E of 32.9, below the industry P/E of 36.0. Looking ahead, it is strengthening its domestic branded portfolio in women's health, cardiac and other chronic therapies and widening its international presence. A mix of branded and export sales spreads risk across geographies.
How has Chalet Hotels performed financially?
Ans. Revenue rose from Rs 530 crore in FY22 to Rs 2,812 crore in FY26, a compound annual growth rate of 51.8%. Net profit grew from Rs 183 crore in FY23 to Rs 645 crore in FY26, which works out to a compound annual growth rate of 52.1%. The company has a return on equity of 17.4%, a debt to equity ratio of 0.64 and a market capitalisation of Rs 18,491 crore. The stock trades at a P/E of 35.0, below the industry P/E of 37.9. Looking ahead, the company is adding rooms at existing hotels and building new properties in cities where business and leisure travel is growing. Its annuity assets, such as office and retail space, add steady rental income alongside hotel earnings.
How has Oil and Natural Gas Corporation performed financially?
Ans. Revenue rose from Rs 498,738 crore in FY22 to Rs 621,019 crore in FY26, a compound annual growth rate of 5.6%. Net profit grew from Rs 32,778 crore in FY23 to Rs 49,793 crore in FY26, which works out to a compound annual growth rate of 15.0%. In the June 2026 quarter, revenue grew 25.5% year on year to Rs 207,776 crore. The company has a return on equity of 11.1%, a debt to equity ratio of 0.47 and a market capitalisation of Rs 282,679 crore. The stock trades at a P/E of 6.3, below the industry P/E of 7.2. Looking ahead, the company is investing in new wells, deepwater projects and field redevelopment to raise output, and it is entering new energy areas such as gas and renewables. Its large reserve base supports long-term production.
What risks should investors check before buying oncology generic, resort and gas well stocks?
Ans. Investors should check a few risks before buying oncology generic, resort and gas well stocks. Regulatory approvals. Plant inspections and approvals can affect supplies. Travel cycles. Bookings and occupancy follow travel demand. Oil and gas prices. Earnings follow crude oil, gas and refining margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of oncology generic, resort and gas well stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
Recent Articles

Top Under Rs 1,200 Stocks Compared: Kalyan Jewellers vs CG Power vs Infosys vs Max Healthcare vs Metro Brands on Price, Valuation, Q2 FY27 Results and Risks
19 November 2026

Top Under Rs 600 Stocks Compared: IRCTC vs Berger Paints vs Aarti Industries vs Honasa Consumer vs Vardhman Textiles on Price, Valuation, Q2 FY27 Results and Risks
19 November 2026

Top Under Rs 400 Stocks Compared: ITC vs NTPC vs KEC International vs Chambal Fertilisers vs Dabur on Price, Valuation, Q2 FY27 Results and Risks
19 November 2026

Top Mid-Cap High-Dividend Stocks Compared: Chennai Petroleum vs IGL vs Petronet LNG vs Emami vs Container Corporation on Price, Valuation, Q2 FY27 Results and Risks
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top Under Rs 1,200 Stocks Compared: Kalyan Jewellers vs CG Power vs Infosys vs Max Healthcare vs Metro Brands on Price, Valuation, Q2 FY27 Results and Risks
Top Under Rs 600 Stocks Compared: IRCTC vs Berger Paints vs Aarti Industries vs Honasa Consumer vs Vardhman Textiles on Price, Valuation, Q2 FY27 Results and Risks
Top Under Rs 400 Stocks Compared: ITC vs NTPC vs KEC International vs Chambal Fertilisers vs Dabur on Price, Valuation, Q2 FY27 Results and Risks
Top Mid-Cap High-Dividend Stocks Compared: Chennai Petroleum vs IGL vs Petronet LNG vs Emami vs Container Corporation on Price, Valuation, Q2 FY27 Results and Risks
Top Small-Cap High-Margin Stocks Compared: IEX vs Lemon Tree Hotels vs Vijaya Diagnostic vs Pokarna vs SCI on Price, Valuation, Q2 FY27 Results and Risks

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





